The three large-scale clinical trials of aspirin referred to in the title of this paper are all cooperative secondary prevention trials of myocardial infarction which my colleagues and I are, or were, coordinating in Baltimore, Maryland. They are the Coronary Drug Project Aspirin Study (CDPA), the results of which have already been published; the Aspirin Myocardial Infarction Study (AMIS) and the Persantine-Aspirin Reinfarction Study (PARIS), both of which are currently under way. All three are similar in organization and design and include both an aspirin and a placebo control group. PARIS also has a group of patients being treated with aspirin and dipyridamole in order to test whether this combination of drugs is better than aspirin alone. It is, of course, no accident that the three studies are similar in design since our group was involved in planning all of them. Further, the latter two came after the CDPA and were undertaken partly because of the results of that study. In this paper I shall first review the results of the CDPA; then discuss the design of the AMIS, indicating where the design of the PARIS differs; and finally present some of the baseline data of the PARIS.
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The CDPA was an outgrowth of the Coronary Drug Project (CDP), a study of lipid-affecting drugs in the secondary prevention of myocardial infarction (MI), which was sponsored by the National Heart, Lung and Blood Institute (NHLBI) of the United States Department of Health, Education, and Welfare. Three treatment groups in the CDP were discontinued for possible adverse effects before the scheduled end of the study. Eligible patients from those treatment groups were rerandomized in the CDPA to one gram of aspirin per day or to placebo in order to evaluate the effect of aspirin in the prevention of mortality and recurrent infarction. The patients were entered into the CDPA during two separate periods (Table 1) Patients were randomly assigned in a doubleblind manner to one of the two treatment groups using a separate randomization schedule for each of the 53 participating clinical centers and each of the three previous CDP treatments. Table 1 shows the distribution of patients in the aspirin and placebo groups for each of the previous CDP groups. The 758 patients assigned to the aspirin group were prescribed one 324 mg aspirin tablet three times a day. The 771 patients in the control group were prescribed a similar placebo tablet three times daily. All tablets were methylcellulose-coated to protect against unblinding of the treatment assignment. Patient follow up was terminated in February 1975 at the time of the scheduled termination of the original CDP. At that time, the total mortality in the aspirin group was 5.8 % compared to 8.3 % in the placebo group, a reduction of 30%. The life tables graphs for total mortality are given in Fig 1. Note that there is a narrow difference between the mortality curves favouring aspirin from Month 4 to Month 16, at which point the difference becomes larger. The Z-value for the aspirin-placebo difference in mortality is 1.90, which is not quite at the level of statistical significance. These and other data from the CDPA have recently been published in the Journal of Chronic Diseases (Coronary Drug Project Aspirin Study 1976) . Suffice it to say that, given observed difference in mortality, the CDPA investigators proposed to the NHLBI that the study be extended and asked for funds for this purpose. This proposal was turned down. The main reason for this rejection was that the CDPA patients were a very select group, having been the survivors from three different treatment groups of the CDP which had been discontinued for adverse findings. This makes generalization and acceptance of the findings very doubtful. Just as an example of this aspect of the difficulties, as I already mentioned, the CDPA patients were, on the average, seven years beyond their most recent MI. This fact makes it very difficult to extrapolate the findings to patients with rec;ent MIs.
Futhermore, as seen in Fig 2, there were some inconsistencies in the data. The positive effect of the aspirin was confined to the patients originally assigned to the dextrothyroxine (DT4) group and high-dose estrogen (ESG2) group, with opposite findings in the third group. Recall that this third group was randomized later than the others, which accounts for the lower mortality than in the other two groups. This does not, of course, explain the reversal of the aspirin effect, nor the generally higher mortality in the ESG2 group as compared to the DT4 group.
In spite of these disconcerting discrepancies, the overall results were very encouraging and in addition the CDPA demonstrated that an aspirin study was feasible. Therefore, the NHLBI mounted a new aspirin study which would not have the shortcomings of the CDPA. This study is the Aspirin-Myocardial Infarction Study or AMIS (Aspirin Myocardial Infarction Research Group 1977) . As a matter of fact, the NHLBI must have set a speed record in initiating AMIS in the summer of 1974, only a few months after the decision to terminate the CDPA, and even before the end of patient follow up in that study. Patient recruitment in AMIS began in the spring of 1975 and was successfully concluded on schedule one year later. AMIS is a prospective clinical trial designed to evaluate the efficacy of aspirin in the secondary prevention of coronary heart disease in men and women, ages 30-69, with previous documented MI.
The original recruitment goal was 4200 patients. In the end, 4524 patients were randomized into AMIS; 2267 into the aspirin group and 2257 into the placebo. The group is quite proud of the fact that it exceeded its recruitment goal within the scheduled period of one year. The last patient entered the study in August 1976 and the study is scheduled to run until the summer of 1979. Thus, all patients will be followed under a common study protocol for at least three years unless a decision is made to terminate earlier because of adverse or beneficial effects. Allocation to treatment group was carried out at the Coordinating Center using a computerized randomization scheme and is double-blind in the sense that neither the patient nor the study physician knows the treatment assignment.
Assignment was to one of two treatments: a 500 mg capsule of aspirin twice a day for the patients assigned to treatment with aspirin; a corresponding placebo capsule twice a day for the patients in the control group. The decision was made to administer two doses a day rather than three as in the CDPA in the hope that this would facilitate adherence to prescription.
Essentially, AMIS patients are men and women between the ages of 30 and 70 and with an ECG-documented MI within five years prior to entry into the study. All patients are New York Heart Association Class I or II and all patients have no history of coronary surgery. Selected I i Table 2 Major response variables Primary endpoints (1) Death (2) patients have uio life-limiting disease other than CHD and are not on aspirin or aspirin-containing drugs, anticoagulants, sufinpyrazone or dypyridamole. They have no history of aspirin reaction or ulcer and their physicians' approval for participation must be obtained.
Patients are examined at the clinical centres three times a year and standard forms are completed and forwarded to the Coordinating Center where the data are compiled and analyzed. The major response variables studied are shown in Table 2 . The primary endpoints of the study are total mortality and recurrent MI although other endpoints are also monitored.
There are thirty Clinical Centers throughout the US, which are responsible for patient management within the study. The Coordinating Center, located at the University of Maryland in Baltimore, is responsible for the collection and analysis of all data from the clinical centres and the other units which include a Central Laboratory, responsible for biochemical analysis of serum and urine specimens; an ECG Reading Center; a Drug Procurement Center; and the Project Office of the NHLBI.
The administrative units of the study include, in particular, the Policy-Data Monitoring Board and the Mortality Classification Committee. The Board supervises the scientific conduct of the study and is responsible for periodically reviewing all study data for beneficial or adverse effects of the treatment and, if necessary, would recommend termination of the study to the NHLB1. The Mortality Classification Committee reviews all the information regarding fatal events, blinded to the individual's treatment assignment, and classifies each death as to cause. Another Com-mittee, not listed here, reviews the reports of recurrent MI and other non-fatal events, also while blinded as to treatment assignment. Recruitment in AMIS was completed about fifteen months ago and the study is on schedule and well into the follow-up phase.
At almost exactly the same time as AMIS, another trial of aspirin was being organized. This is the Persantine-Aspirin Reinfarction Study (1976) or PARIS as it is commonly referred to.
PARIS was designed and organized to test the efficacy, not of aspirin versus placebo, but of the combination of Persantine (dipyridamole) and aspirin versus aspirin alone. However, the study planners were not willing to accept as proven the efficacy of aspirin alone, and in spite of the fact that AMIS was also being organized, a placebo group was included in the PARIS design. Thus, in effect, the PARIS provides us with another clinical trial of aspirin. Although the design and organization of AMIS and PARIS are quite similar, there are certain differences which I would like to point out.
The first obvious difference is that AMIS is sponsored by the NHLBI while the funds for PARIS come from Boehringer-Ingelheim, the manufacturers of Persantine. However, in no way can we regard PARIS as the typical drug company study. As in AMIS, the supervision of the study is under the control of an independent Policy Board. The fnnds for the study have been donated without conditions to the Maryland Medical Research Institute in Baltimore, which serves as the PARIS Coordinating Center. Some of us in Baltimore serve on both the AMIS and PARIS staffs in different capacities.
The organizational structure of PARIS is like that of AMIS, except that PARIS has a Data Monitoring Committee in addition to, and separate from, the Policy Board. This committee has the primary responsibility of reviewing the data and making recommendations to the Policy Board concerning changes in study protocol because of adverse or beneficial drug effects. This system provides for a double review of the data and additional assurance that the study is conducted to the best scientific principles.
PARIS was originally scheduled to terminate patient follow up in June 1977 after one year of follow up for all patients. However, upon the recommendations of the Data Monitoring Committee and the Policy Board, the study was extended to June 1978 and there is a possibility it may be extended beyond that point.
Another unique feature of the PARIS organization is the existence of a Data Quality Control Center whose role is to monitor the performance of the Coordinating Center to guarantee that the data are being collected and analyzed appropriately.
One interesting aspect of the PARIS organization is that four of its twenty Clinical Centers are located in Great Britain; namely in London and Hull, England, and in Aberdeen and Glasgow, Scotland. PARIS is a smaller study than AMIS, with a total of 2026 patients who were recruited between May 1975 and September 1976; also on schedule, I might add. These patients were assigned randomly and double-blind to the three treatment groups; 810 to aspirin, 810 to treatment with both Persantine and aspirin, and 406 to the placebo control group. The daily aspirin dose is 972 mg. It is administered in tablets of 324 mg each, given three times a day, as in the CDPA; whereas in AMIS, as I have said, it is administered in two capsules daily.
The eligibility requirements for enrolment into PARIS were almost exactly the same as the AMIS, except that patients were enrolled up to age 75 instead of 70 as in AMIS. The patient follow-up schedule and procedures are not very different from those of AMIS.
About 87% of the PARIS patients are male;
for AMIS, the figure is 89 %. In the CDPA, only males were enrolled. The age range is from 30 to 75 with a mean age of 56 years, which is only one year more than the AMIS mean of 55 years. Even though the upper age limit for PARIS is 75 compared to 70 for AMIS, only 5.2% of the patients are in the group aged 70 or greater. Surprisingly enough, and because the original CDP patients were younger, the mean age for CDPA patients is also about 56 years.
About 82 % of the PARIS patients had only one MI previous to entry into the study; the cor-responding figure for AMIS is 87% while in the CDPA only about 76% of the patients had a single MI. Some 16% of the PARIS patients are non-smokers, 57 % are former cigarette smokers, and 27 % are currently smoking cigarettes. The AMIS figures are quite similar. The CDPA, for some reason, did not obtain the history of cigarette smoking, but about 30 % of CDPA patients were smokers at the time of entry into that study. Further, the bulk of patients in the three studies are married; about 85% in AMIS and PARIS versus 89% in the CDPA. Most are white: 97% in PARIS, 92-% in AMIS, and 94% in the CDPA.
Three-quarters of the patients reported using aspirin less than once a month, on the average, before entry into the study. Whether this is a true figure or represents the patients' incorrect perception of the situation remains to be seen. I should mention here that patients in these studies were supplied with acetaminophen or paracetamol to use as an analgesic in lieu of aspirin.
These data represent only a portion of the measurements made at baseline, all of which will be taken into account when assessing the treatment effects on the outcome. Within each study, there are some slight differences in distributions across treatment groups, as expected, but these differences will be adjusted for in the analyses using methods such as the analysis of covariance and the Cox method of lifetable analysis. Of course, none of the follow-up data can be discussed until the studies are completed. We are hopeful that, at that time, the results of the analyses from these two parallel studies will also be parallel so that we may make some conclusions concerning the role of aspirin in the therapy of post-MI patients.
